Paragon 28 Announces Changes to its Board of Directors
04 August 2022 - 2:00PM
Business Wire
Paragon 28, Inc. (NYSE: FNA), a leading medical device company
exclusively focused on the foot and ankle orthopedic market, today
announced two changes to the composition of its Board of
Directors.
Quentin Blackford has joined the Company’s Board of Directors
and will serve the Company as Chairman of its Compensation
Committee and as a member of its Audit Committee. Mr. Blackford has
more than two decades of senior leadership experience with global
medical device companies. He currently serves as President, Chief
Executive Officer, and Director of iRhythm Technologies (NASDAQ:
IRTC), a leading digital healthcare solutions company.
“We are very excited to have Quentin join our Board of
Directors,” said Albert DaCosta, CEO and Chairman of Paragon 28.
“Quentin has one of the most impressive track records in
high-growth med-tech, and has led some of the most successful
medical device companies of the last decade. I look forward to
partnering with Quentin to advance our mission of improving foot
and ankle patient outcomes.”
Prior to iRhythm Technologies, Mr. Blackford served at Dexcom,
Inc. from 2017 to 2021, first as Chief Financial Officer and then
as Chief Operating Officer. Prior to Dexcom, Mr. Blackford served
at Nuvasive, Inc. from 2009 to 2017, including as Chief Financial
Officer and as Head of Strategy and Corporate Integrity from 2014
to 2017. Prior to 2009, Mr. Blackford served at Zimmer Biomet, Inc.
(NYSE: ZBH) in various senior financial leadership positions. Since
October 2017, Mr. Blackford has also served as a member of the
board of directors of Alphatec Holdings, Inc. (NASDAQ: ATEC), where
he serves on the compensation committee and audit committee. Mr.
Blackford is a Certified Public Accountant (inactive) and received
dual Bachelor of Science degrees in Accounting and Business
Administration from Grace College.
Also, Scott Drake has transitioned from the Company’s Board of
Directors. “I am very grateful to Scott for his service to Paragon
28. Scott has been a strong leader and a trusted advisor, and was
instrumental in P28’s successful IPO, and seamless transition to a
top performing public company,” said Albert DaCosta, CEO and
Chairman of Paragon 28.
About Paragon 28, Inc.
Based in Englewood, Colo., Paragon 28, is a leading medical
device company exclusively focused on the foot and ankle orthopedic
market and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, hallux
valgus (bunions), hammertoe, ankle, progressive collapsing foot
deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The
company designs products with both the patient and surgeon in mind,
with the goal of improving outcomes, reducing ailment recurrence
and complication rates, and making the procedures simpler,
consistent, and reproducible.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220804005094/en/
Gilmartin Group Matt Bacso, CFA matt.bacso@gilmartinir.com
Paragon 28 (NYSE:FNA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Paragon 28 (NYSE:FNA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024